4,4,4-trifluoro-1-phenyl-1,3-butanedione: can trap reactive metabolites of carcinogens
ID Source | ID |
---|---|
PubMed CID | 67589 |
CHEMBL ID | 421036 |
SCHEMBL ID | 523476 |
MeSH ID | M0204425 |
Synonym |
---|
HMS1765N10 |
benzoyltrifluoroacetone |
1,3-butanedione, 4,4,4-trifluoro-1-phenyl- |
1-benzoyl-3,3-trifluoroacetone |
.omega.-(trifluoroacetyl)acetophenone |
nsc42628 |
1-benzoyl-3,3-trifluoro-2-propanone |
3-benzoyl-1,1-trifluoroacetone |
nsc-42628 |
benzoyl(trifluoroacetyl)methane |
326-06-7 |
1, 4,4,4-trifluoro-1-phenyl- |
4,4,4-trifluoro-1-phenylbutane-1,3-dione |
4,4,4-trifluoro-1-phenyl-butane-1,3-dione |
4,4,4-trifluoro-1-phenyl-1,3-butanedione, 99% |
STK400152 |
AKOS000210550 |
bdbm50121960 |
CHEMBL421036 , |
4,4,4-trifluoro-1-phenyl-1,3-butanedione |
T0437 |
A18637 |
3-benzoyl-1,1,1-trifluoroacetone |
nsc 42628 |
omega-(trifluoroacetyl)acetophenone |
einecs 206-307-8 |
1-benzoyl-3,3,3-trifluoroacetone |
1-benzoyl-3,3,3-trifluoro-2-propanone |
dtxsid2049268 , |
NCGC00260367-01 |
dtxcid1029124 |
tox21_202821 |
cas-326-06-7 |
benzoyl-1,1,1-trifluoroacetone |
BBL013135 |
1-phenyl-4,4,4-trifluorobutane-1,3-dione |
FT-0622745 |
SCHEMBL523476 |
1-phenyl-4,4,4-trifluoro-butane-1,3-dione |
1,1,1-trifluoro-4-phenyl-2,4-butanedione |
1-phenyl-4,4,4-trifluoro-1,3-butanedione |
4-phenyl-1,1,1-trifluorobutane-2,4-dione |
F0348-2294 |
SR-01000389031-1 |
sr-01000389031 |
mfcd00000425 |
J-018802 |
SY021552 |
AS-40413 |
potassiumhexafluorozirconate |
Q63395499 |
EN300-17299 |
CS-W014860 |
1,1,1-trifluoro-4-phenyl-butane-2,4-dione |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 64.2427 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 62.5737 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.9567 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
AR protein | Homo sapiens (human) | Potency | 25.6373 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381; AID743035; AID743063 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 34.7341 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 8.7580 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 28.4547 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0012 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 9.6645 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1259401 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 55.2593 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 33.9084 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743079; AID743080; AID743091 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 55.7688 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 24.6834 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 43.5209 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385 |
thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 36.9107 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 39.4813 | 0.0578 | 21.1097 | 61.2679 | AID1159528 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 69.5673 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 60.8235 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 17.4745 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 69.5673 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 17.4745 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 43.8940 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 43.8940 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1332962 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by REMA method | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. |
AID475184 | Inhibition of Pseudomonas aeruginosa beta-lactamase AmpC at 2 uM | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8 | 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity. |
AID85243 | In vitro cytotoxic activity against human squamous cell carcinoma (HSC-2) cells. | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Alpha-trifluoromethylated acyloins induce apoptosis in human oral tumor cell lines. |
AID82566 | In vitro cytotoxic activity against human gingival fibroblasts (HGF). | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Alpha-trifluoromethylated acyloins induce apoptosis in human oral tumor cell lines. |
AID85248 | In vitro cytotoxic activity against human salivary gland tumor (HSG) cells. | 1999 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21 | Alpha-trifluoromethylated acyloins induce apoptosis in human oral tumor cell lines. |
AID208331 | Binding to stromelysin (MMP-3) in place of acetohydroxamic acid. | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26 | NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.30) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |